Professor Jean-Charles Soria
Annals of Oncology - Best of 2016
To mark the end of the year Professor Soria and his team pick a selection of the best articles published in Annals of Oncology in 2016.
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial
H. H. Yoon; J. C. Bendell; F. S. Braiteh; I. Firdaus; P. A. Philip ...
Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial
J. Quidde; S. Hegewisch-Becker; U. Graeven; C. A. Lerchenmüller; B. Killing ...
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)
W. M. Tai; W. P. Yong; C. Lim; L. S. Low; C. K. Tham ...
The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy
F. Perrone; C. Jommi; M. Di Maio; A. Gimigliano; C. Gridelli ...
Perspectives of health care professionals on cancer cachexia: results from three global surveys
M. Muscaritoli; F. Rossi Fanelli; A. Molfino
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)
J. Sehouli; R. Chekerov; A. Reinthaller; R. Richter; A. Gonzalez-Martin ..
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study
S. Kanda; K. Goto; H. Shiraishi; E. Kubo; A. Tanaka ...
Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
S. Genadieva-Stavrik; A. Boumendil; P. Dreger; K. Peggs; J. Briones ...
Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer
R. L. Ferris; J. L. Geiger; S. Trivedi; N. C. Schmitt; D. E. Heron ...
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
J. C. Soria; H. K. Gan; S. P. Blagden; R. Plummer; H. T. Arkenau ...
Antiangiogenic therapies in gastric cancer: trusting the pathway
M. Alsina; C. Hierro; J. Tabernero
On the generalizability of prostate cancer studies: why race matters
O. Oren; M. Oren; D. Beach
Ovarian cancer mortality trends: which factors are involved?
E. Weiderpass; E. Botteri
Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment
C. S. Voican; O. Mir; P. Loulergue; M. Dhooge; C. Brezault ...
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
C. Coyle; F. H. Cafferty; C. Vale; R. E. Langley
The obese endometrial cancer patient: how do we effectively improve morbidity and mortality in this patient population?
K. Papatla; M. Huang; B. Slomovitz
Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues
E. Bentivegna; S. Gouy; A. Maulard; P. Pautier; A. Leary ...
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
K. A. Olaussen; S. Postel-Vinay
Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis
D. De Ruysscher; on behalf of the RTT-SCLC Collaborative Group; B. Lueza; on behalf of the RTT-SCLC Collaborative Group; C. Le Péchoux ...
Chemotherapy remains an essential element of personalized care for persons with lung cancers
M. D. Hellmann; B. T. Li; J. E. Chaft; M. G. Kris
Impact Factor increases to 9.269
Access our free collection of highly cited articles which contributed to Annals of Oncology’s new Impact Factor of 9.269
Explore papers focusing on patient-centred oncology research and care from the Oxford University Press medical journals.
The Best of 2016
Explore a collection of the best articles of 2016 from Annals of Oncology.
Why Publish with Annals of Oncology?
Give your research the global platform it deserves; submit to Annals of Oncology, one of the most widely read and cited journals in Oncology.
The latest research, on the go
Get fast and convenient access to every issue of Annals of Oncology from our app – free to download from the iTunes store.
Recommend to your library
Fill out our simple online form to recommend this journal to your library.